10 completed. 10 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 7 | Completed 7 |
Follow Matrix-M: new trials by email Literature Review of Matrix-M trials Research Report on Matrix-M
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults R21, Pfs230D1-CRM197, Pfs230D1-EPA - Prevention of Malaria Transmission and Clinical Malaria | Phase 1 | Completed | Serum Institute of India Pvt. Ltd. | 240 | 2024-08-30 | 2026-02-10 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 Matrix-M with RH5.2 VLP and/or R21 - Malaria, Plasmodium Falciparum | Phase 1 | Completed | University of Oxford | 107 | 2023-07-10 | 2026-05-12 |
| A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 390 | 2023-04-03 | 2026-10-21 |
| Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant - SARS-CoV Infection, Covid19 | Phase 1 / Phase 2 | Completed | Novavax | 637 | 2021-09-08 | 2025-04-10 |
| Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 PvDBPII/Matrix-M1 - Malaria, Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 24 | 2020-01-24 | 2024-11-25 |
| Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 450 | 2019-05-07 | 2025-07-11 |
| A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP R21 with Matrix-M1, ChAd63 ME-TRAP, MVA ME-TRAP - Malaria | Phase 1 / Phase 2 | Completed | University of Oxford | 63 | 2016-08-01 | 2018-06-13 |
| A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1 R21, Matrix-M1 - Malaria | Phase 1 | Completed | University of Oxford | 31 | 2015-10-15 | 2019-11-12 |
Malaria, Falciparum (4) · Malaria (3) · COVID-19 (1) · Coronavirus Infections (1) · Epstein-Barr Virus Infections (1) · Herpes Simplex (1) · Infections (1) · Infectious Mononucleosis (1) · Malaria, Vivax (1) · Parasitic Diseases (1) · Severe Acute Respiratory Syndrome (1) · Vector Borne Diseases (1)
University of Oxford (7) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novavax (1) · Serum Institute of India Pvt. Ltd. (1)
United Kingdom (4) · Burkina Faso (2) · Australia (1) · Mali (1) · The Gambia (1) · United States (1)
Adrian V Hill, DPhil FRCP (1) · Angela M Minassian, Dr (1) · Angela Minassian (1) · Angela Minassian, Dr (1) · Jessica R Durkee-Shock, M.D. (1) · Umberto D'Alessandro (1)
PMID 30774635, PMID 33964223, PMID 35664997, PMID 36087586, PMID 39672183, PMID 39805301, PMID 39805302, PMID 40245769, PMID 41176969